These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35599019)

  • 21. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
    Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
    BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCR-ABL1 p210 screening for chronic myeloid leukemia in patients with peripheral blood cytoses.
    Fenu E; O'Neill SS; Insuasti-Beltran G
    Int J Lab Hematol; 2021 Dec; 43(6):1458-1464. PubMed ID: 34185393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: the threats and challenges in monitoring minimal residual disease (MRD).
    Vaniawala S; Acharya A; Parekh H; Mukhopadhyaya PN
    Anal Cell Pathol (Amst); 2013; 36(3-4):85-92. PubMed ID: 24072036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome.
    Westbrook CA
    Cancer; 1992 Sep; 70(6 Suppl):1695-700. PubMed ID: 1516023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
    Hughes T; Branford S
    Blood Rev; 2006 Jan; 20(1):29-41. PubMed ID: 16426942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
    Lu X; Song X; Ye Y; Liu X; Zhou Y; Zhang L; Wang J; Ying B; Wang L
    Mol Biol Rep; 2011 Jun; 38(5):3101-5. PubMed ID: 20127176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular events in chronic myeloid leukemia progression.
    Guerrasio A; Serra A; Gottardi E; Cilloni D; Vischia F; Parvis G; Cilli V; Saglio G
    Leukemia; 1997 Apr; 11 Suppl 3():519-21. PubMed ID: 9209443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescence in situ hybridization: a highly efficient technique of molecular diagnosis and predication for disease course in patients with myeloid leukemias.
    Amare PS; Baisane C; Saikia T; Nair R; Gawade H; Advani S
    Cancer Genet Cytogenet; 2001 Dec; 131(2):125-34. PubMed ID: 11750052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.
    Zámečníkova A; Al Bahar S; Pandita R
    Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia.
    Chandran RK; Geetha N; Sakthivel KM; Aswathy CG; Gopinath P; Raj TVA; Priya G; Nair JKKM; Sreedharan H
    Gene; 2019 Feb; 686():85-91. PubMed ID: 30399426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
    Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
    Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.
    Huet S; Cony-Makhoul P; Heiblig M; Tigaud I; Gazzo S; Belhabri A; Souche D; Michallet M; Magaud JP; Hayette S; Nicolini F
    PLoS One; 2014; 9(9):e106250. PubMed ID: 25203717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
    Latham S; Bartley PA; Budgen B; Ross DM; Hughes E; Branford S; White D; Hughes TP; Morley AA
    J Clin Pathol; 2016 Sep; 69(9):817-21. PubMed ID: 26837312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
    Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
    Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
    Razga F; Jurcek T; Zackova D; Dvorakova D; Toskova M; Jeziskova I; Mayer J; Racil Z
    Mol Diagn Ther; 2012 Aug; 16(4):251-9. PubMed ID: 22873741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices.
    Arora R; Press RD
    Leuk Lymphoma; 2017 Jan; 58(1):8-16. PubMed ID: 27412040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.